166
Views
27
CrossRef citations to date
0
Altmetric
Articles

Calprotectin (a major leucocyte protein) is associated with the levels of anti‐CCP and rheumatoid factor in a longitudinal study of patients with very early rheumatoid arthritis

, &
Pages 179-182 | Accepted 18 Dec 2007, Published online: 12 Jul 2009
 

Abstract

Background: Calprotectin is a major granulocyte and monocyte protein, and plasma levels of calprotectin are strongly associated with inflammation in patients with rheumatoid arthritis (RA).

Objective: To explore the associations between calprotectin and serological, inflammatory, and clinical assessments in a longitudinal study of patients with very early RA.

Patients and methods: In 61 RA patients (77% females, mean age 57.9 years, disease duration 132 days), laboratory and clinical assessments were performed at baseline and after 3, 6, and 12 months.

Results: Calprotectin levels were higher in patients positive vs. negative for anti‐cyclic citrullinated peptide (anti‐CCP), immunoglobulin M rheumatoid factor (IgM‐RF), and IgA‐RF (p<0.001–0.05). The 1‐year averaged level of calprotectin correlated significantly with the mean levels of these three serological markers (p<0.05). In multiple regression analyses, adjusting for age, sex, and disease duration, calprotectin was associated with anti‐CCP (p = 0.045), and both calprotectin and erythrocyte sedimentation rate (ESR) were associated with IgM‐RF (p = 0.003 and 0.03, respectively). Calprotectin correlated significantly with the inflammatory markers at all examinations [C‐reactive protein (CRP); r = 0.60–0.70, p<0.001, ESR; r = 0.55–0.57, p<0.001] as well as with the 28‐joint disease activity score (DAS28; r = 0.28–0.33, p<0.05).

Conclusion: This is the first study that shows significant associations between the levels of calprotectin and anti‐CCP, IgA‐RF, and IgM‐RF in very early RA. In addition, significant correlations were found between calprotectin and markers of disease activity.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.